Safety and Comfort of AL-4943A Ophthalmic Solution

• Status: Completed
• Trial end date: 2011-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the ocular comfort and safety of olopatadine hydrochloride opthalmic solution. 0.7%.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Alcon Research
• Treatments: Ketotifen; Olopatadine Hydrochloride; Ophthalmic Solutions; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Able to be dosed in both eyes, to follow instructions, and willing and able to attend required study visits.

• Negative urine pregnancy test if female of childbearing potential and use adequate birth control throughout the study period.

• Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

• History or clinical evidence of ocular herpes simplex or ocular herpes zoster infectious disease.

• History of any clinically significant external ocular disease within 30 days of the start of the study.

• Presence of active blepharitis, active meibomian gland dysfunction, active rosacea affecting the ocular surface/lid margin, active or chronic follicular conjunctivitis, preauricular adenopathy, or any other ocular or periocular abnormality that may affect the study outcomes.

• Other protocol-defined exclusion criteria may apply.